Key result
Female ischemic stroke patients treated with intravenous thrombolysis had higher unadjusted 3-month mortality (26.0% vs 19.7%) than men, though sex itself was not an independent predictor of worse outcomes after adjusting for baseline differences.
Why the study?
The authors sought to investigate sex differences in ischaemic stroke patients treated with intravenous alteplase.
Does female sex impact outcomes in ischemic stroke patients treated with intravenous alteplase?
Cohort (n=1,830)
Yes
Does female sex impact outcomes in ischemic stroke patients treated with intravenous alteplase?
Absolute Event Rate: 26% vs 19.7%
p-value: p=< 0.01
Women treated with intravenous alteplase for ischemic stroke have worse long-term outcomes than men, which is largely explained by their older age and higher proportion of cardio-embolic strokes rather than sex itself.
Thrombolysis eligibility should remain sex-neutral; leaves open residual confounding in observational stroke cohorts.
AIM OF STUDY: We investigated sex differences i n i schaemic s troke p atients t reated w ith i ntravenous a lteplase. CLINICAL RATIONALE FOR STUDY: We suggest that it is necessary to improve care for women with atrial fibrillation. Our data suggests that closer evaluation of treatment for ischaemic stroke in men and women is needed, preferably in the form of a prospective study. MATERIALS AND METHODS: This was a multicentre analysis of 1,830 ischaemic stroke patients treated with alteplase from 2004 to 2012. Data was prospectively collected in the Safe Implementation of Treatments in Stroke (SITS) registry. The main outcome measures were symptomatic intracerebral haemorrhage (sICH) within 36 hours of treatment, three months of functional independence, and mortality. RESULTS: Women were significantly older (mean age 71.3 vs 66.2 years; p < 0.01), more often suffered from hypertension (78.3% vs 70.1%; p < 0.01) and cardio-embolic strokes (34.7% vs 27.1%; p < 0.01), and presented heavier baseline deficits. There were no differences in sICH, but after three months fewer women were functionally independent (46.5% vs 53.3%; p < 0.01) and women had higher mortality (26.0% vs 19.7%; p < 0.01). CONCLUSIONS: Of the ischaemic stroke patients treated with intravenous thrombolysis, women had worse long-term outcomes than men. This discrepancy may be explained by the older age and higher proportion of cardio-embolic strokes with more severe baseline deficits. However, multiple logistic analysis did not show that sex itself had an impact on the greater mortality in women after a stroke, or on the poorer prognosis.
No takes yet. Share an insight, caveat, or question.
Wiszniewska et al. (2020) conducted a cohort in Ischaemic stroke (n=1,830). Female sex vs. Male sex was evaluated on 3-month mortality (p=< 0.01). Female ischemic stroke patients treated with intravenous thrombolysis had higher unadjusted 3-month mortality (26.0% vs 19.7%) than men, though sex itself was not an independent predictor of worse outcomes after adjusting for baseline differences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: